A genetically engineered cold sore virus has recently been approved by the FDA has a new treatment for melanoma. According to Dr. Karen Midthun, director of the FDA's Center for Biologics Evaluation and Research, this new therapy, known as Imlygic, showed promising results in a study of 436 patients; those injected with Imlygic had a 16% decrease in tumor size compared to those receiving other forms of treatment.
To read more about this study, click here.
No comments:
Post a Comment